A

Alexion

Global biopharmaceuticals focusing on rare diseases

Regional Account Manager - NF1 PN

Full-TimePosted on 10/23/2026Deadline 11/6/26
$173.1k - $259.7k/yr+ Short-term incentive bonuses + Equity-based awards + Sales commissions
Senior
Bachelor's, Master's
Philadelphia, PA, USA+1 moreMore locations: Newark, NJ, USA
In PersonField-based role with regular territory travel, including frequent overnight and weekend travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree is required.
  • At least 6 years of pharmaceutical or equivalent experience, such as biotechnology or medical device experience, including 3 years of biotechnology or pharmaceutical sales experience calling on institutions and hospital systems.
  • At least 2 years of documented successful pharmaceutical or healthcare sales experience in oncology, rare disease, or a relevant therapeutic area.
  • Ability to manage the complexity of a systems approach and develop multidisciplinary teams in institutions.
  • Strong institutional navigation and stakeholder influence-mapping capabilities.
  • Ability to engage diverse specialties and disciplines.
  • A proven, documented track record of delivering consistent top-tier sales results in institutions and hospital systems.
  • Ability to work effectively independently and in an interdependent, team-oriented environment.
  • Demonstrated ability to seek out and qualify leads and profile new accounts.
  • Ability to gain consistent access to healthcare providers in institutions, integrated delivery networks, and academic centers, and develop professional relationships for scientific exchange and promotion.
  • Ability to efficiently manage time, customer relationship management tools, resources, and workload.
  • Effective verbal and written communication skills and organizational abilities.
  • Ability to travel regularly within the territory, including frequent overnight and weekend travel.
  • Valid driver's license and clean driving record.
  • Ability to perform field-based duties, including travel by public transportation, automobile, train, or plane; work comfortably in a clinical setting; use a computer; communicate via phone, video, and electronic messaging; problem-solve; engage in complex analysis and dialogue; collaborate with others; and maintain general availability during standard business hours, with or without accommodation.
Responsibilities
  • Deliver education on disease state, patient identification, NF1 PN management, and rare disease product information to healthcare professionals, primarily in regional hospitals and centers of excellence within a defined geographic territory.
  • Achieve sales objectives and develop relationships across the patient journey within aligned institutions and surrounding hospital service areas.
  • Develop long-term relationships with key customers and maintain clinical expertise by consistently using available medical information resources.
  • Develop and deliver clinical sales presentations to groups of healthcare personnel, and maximize physician contact by networking within accounts and at medical meetings.
  • Achieve or exceed sales objectives in the assigned territory and execute tailored hospital selling to drive results.
  • Create and maintain strategically targeted, account-specific business plans that reflect an in-depth understanding of local market forces affecting product sales.
  • Develop and maintain in-depth clinical, technical, and scientific knowledge and engage in dialogue at a high clinical level.
  • Collaborate with stakeholders, including territory and strategic account leads, medical science liaisons, field reimbursement managers, market access, diagnostics, and other enterprise partners.
  • Address customer questions and objections consistently with product indications and sales training methodology, and compliantly triage inquiries to appropriate partners.
  • Educate customers on the clinical approach to disease state to support successful and accurate diagnosis.
  • Learn to explain and demonstrate proper product use to clinicians and associated healthcare teams in a hospital environment.
  • Lead implementation of the patient-centric partnership model involving physicians, their staff, patients, clinics, and hospitals.
  • Seek out and qualify leads and profile new accounts.
  • Track sales activities and submit accurate, timely reports.
  • Interact proactively with company management to refine product and market initiatives.
  • Manage time, priorities, customer relationship management tools, resources, and workload efficiently.
  • Perform work in alignment with the company's Code of Ethics and Business Conduct and its policies and procedures.
Desired Qualifications
  • An advanced or master's degree.
  • Biopharmaceutical experience.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old